These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 30592031)

  • 1. Nivolumab-induced bullous pemphigoid after radiotherapy and abscopal effect.
    Grimaux X; Delva R; Jadaud E; Croue A
    Australas J Dermatol; 2019 Aug; 60(3):e235-e236. PubMed ID: 30592031
    [No Abstract]   [Full Text] [Related]  

  • 2. Development of bullous pemphigoid following radiation therapy combined with nivolumab for renal cell carcinoma: A case report of abscopal toxicities.
    Huynh LM; Bonebrake BT; DiMaio DJ; Baine MJ; Teply BA
    Medicine (Baltimore); 2021 Dec; 100(49):e28199. PubMed ID: 34889301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nivolumab-associated bullous pemphigoid reactions involving multiple epitopes.
    Aoki Y; Miyagawa F; Miyashita K; Nishimura Y; Hashimoto T; Asada H
    Eur J Dermatol; 2019 Oct; 29(5):552-554. PubMed ID: 31570326
    [No Abstract]   [Full Text] [Related]  

  • 4. Bullous pemphigoid associated with the 480-mg nivolumab dose in a patient with metastatic renal cell carcinoma.
    Palla AR; Smith E; Doll D
    Immunotherapy; 2019 Oct; 11(14):1187-1192. PubMed ID: 31462105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bullous pemphigoid induced by ipilimumab in a patient with metastatic malignant melanoma after unsuccessful treatment with nivolumab.
    Kuwatsuka Y; Iwanaga A; Kuwatsuka S; Okubo Y; Murayama N; Ishii N; Hashimoto T; Utani A
    J Dermatol; 2018 Jan; 45(1):e21-e22. PubMed ID: 28944534
    [No Abstract]   [Full Text] [Related]  

  • 6. Dyshidrosiform pemphigoid due to nivolumab therapy.
    Hayashi W; Yamada K; Kumagai K; Kono M
    Eur J Dermatol; 2021 Jun; 31(3):411-412. PubMed ID: 34309527
    [No Abstract]   [Full Text] [Related]  

  • 7. Bullous pemphigoid developing upon immune checkpoint inhibition with nivolumab.
    Grän F; Goebeler M; Gesierich A
    Eur J Dermatol; 2019 Aug; 29(4):448-449. PubMed ID: 31625927
    [No Abstract]   [Full Text] [Related]  

  • 8. Bullous pemphigoid associated with nivolumab, a programmed cell death 1 protein inhibitor.
    Kwon CW; Land AS; Smoller BR; Scott G; Beck LA; Mercurio MG
    J Eur Acad Dermatol Venereol; 2017 Aug; 31(8):e349-e350. PubMed ID: 28129461
    [No Abstract]   [Full Text] [Related]  

  • 9. Rituximab Treatment of Nivolumab-Induced Bullous Pemphigoid.
    Sowerby L; Dewan AK; Granter S; Gandhi L; LeBoeuf NR
    JAMA Dermatol; 2017 Jun; 153(6):603-605. PubMed ID: 28355425
    [No Abstract]   [Full Text] [Related]  

  • 10. Novel use of combination therapeutic plasma exchange and rituximab in the treatment of nivolumab-induced bullous pemphigoid.
    Ridpath AV; Rzepka PV; Shearer SM; Scrape SR; Olencki TE; Kaffenberger BH
    Int J Dermatol; 2018 Nov; 57(11):1372-1374. PubMed ID: 29624655
    [No Abstract]   [Full Text] [Related]  

  • 11. Bullous pemphigoid exacerbated by nivolumab and temporally rescued with therapeutic plasma exchange.
    Waki Y; Nobeyama Y; Chujo S; Asahina A
    J Dermatol; 2024 May; 51(5):e149-e150. PubMed ID: 38010735
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical and dermoscopical presentation of nivolumab-induced pemphigoid in a metastatic melanoma patient.
    Chersi F; Conforti C; Zalaudek I; Bazzacco G; Zelin E; di Meo N
    Melanoma Res; 2023 Jun; 33(3):262-263. PubMed ID: 37114722
    [No Abstract]   [Full Text] [Related]  

  • 13. Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: A case report.
    Mari R; Guerin M; Vicier C; Walz J; Bonnet N; Pignot G; Gravis G
    Front Immunol; 2022; 13():984132. PubMed ID: 36189265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA adverse event reporting system.
    Aggarwal P
    Expert Opin Drug Saf; 2019 Jul; 18(7):623-633. PubMed ID: 31088310
    [No Abstract]   [Full Text] [Related]  

  • 15. Lichen planus pemphigoides developing from patient with non-small-cell lung cancer treated with nivolumab.
    Sato Y; Fujimura T; Mizuashi M; Aiba S
    J Dermatol; 2019 Oct; 46(10):e374-e375. PubMed ID: 31062404
    [No Abstract]   [Full Text] [Related]  

  • 16. Eruptive keratoacanthomas secondary to nivolumab immunotherapy.
    Bednarek R; Marks K; Lin G
    Int J Dermatol; 2018 Mar; 57(3):e28-e29. PubMed ID: 29318617
    [No Abstract]   [Full Text] [Related]  

  • 17. [A Case of Nivolumab-Induced Isolated Adrenocorticotropic Hormone Deficiency Presenting Dyspnea].
    Ito K; Uchida T; Manabe Y; Miyazaki Y; Itoh H; Mishina M; Okuno H
    Hinyokika Kiyo; 2018 Oct; 64(10):391-395. PubMed ID: 30543736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fatal Acute Motor Axonal Neuropathy Induced by Nivolumab: A Case Report and Literature Review.
    Yildirim N; Gonen M; Balgetir F; Er MB
    Clin Genitourin Cancer; 2019 Dec; 17(6):e1104-e1107. PubMed ID: 31471269
    [No Abstract]   [Full Text] [Related]  

  • 19. Cyclosporine for Recalcitrant Bullous Pemphigoid Induced by Nivolumab Therapy for Malignant Melanoma.
    Wallace CE; Tam I; Beveridge MG
    Cutis; 2024 Jul; 114(1):E21-E23. PubMed ID: 39159347
    [No Abstract]   [Full Text] [Related]  

  • 20. Immune checkpoint inhibitors myocarditis: not all cases are clinically patent.
    Thibault C; Vano Y; Soulat G; Mirabel M
    Eur Heart J; 2018 Oct; 39(38):3553. PubMed ID: 30107497
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.